# Identification of Safety Biomarkers for Autologous Blood Transfusion in Hepatocellular Carcinoma Patients

**Authors:** Yong Cheng, Yue Wang, Xiao‐fang Zhou, Lai‐wei You, Xiao‐yi Xie, Hao Li, Mandi Wu, Jianrong Guo

PMC · DOI: 10.1111/jcmm.70504 · Journal of Cellular and Molecular Medicine · 2025-04-07

## TL;DR

This study identifies biomarkers that indicate the safety of autologous blood transfusion in liver cancer patients undergoing surgery.

## Contribution

The study identifies safety biomarkers for autologous blood transfusion in hepatocellular carcinoma patients using IOCS.

## Key findings

- The experimental group showed increased PTEN-positive cells and upregulated PTEN, mTOR, c-Met, and IGF1R protein expression.
- Key miRNAs (miRNA-21, miRNA-122, etc.) were significantly reduced in the experimental group.
- IOCS positively impacts liver tissue pathology by reducing apoptosis and modulating molecular pathways.

## Abstract

Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer, constituting 75%–85% of all liver cancer cases. Despite advances in understanding HCC mechanisms and treatment options, challenges remain and further research is needed to uncover new therapeutic targets and improve patient outcomes. intraoperative cell salvage (IOCS) is an important surgical method that minimises the necessity for transfusions of donor blood, improves haemodynamic stability and may enhance recovery. This study aims to identify safety biomarkers for autologous blood transfusion in HCC patients. We conducted a prospective case–control study on 80 HCC patients undergoing radical surgery. Blood and tumour tissues were collected for analysis. The control group provided blood directly from the surgical site without IOCS processing, while the experimental group used blood collected through the IOCS system. Dual‐Luciferase reporter gene assays, immunofluorescence, Western blot and qRT‐PCR techniques were employed to assess the expression of key proteins and microRNAs. Comparable demographic and baseline clinical characteristics were observed between groups. The experimental group showed significantly improved pathological features, with an increase in PTEN‐positive cells and upregulated protein expression of PTEN, mTOR, c‐Met and IGF1R. Additionally, miRNA levels (miRNA‐21, miRNA‐122, miRNA‐223, miRNA‐199a and miRNA‐375) were significantly reduced in the experimental group (p < 0.05), while mRNA levels for PTEN, mTOR, c‐Met, YAP1 and IGF1R were significantly upregulated (p < 0.05). IOCS has a positive impact on liver tissue pathology in HCC patients by reducing apoptosis and modulating key molecular pathways. These findings suggest that IOCS could be a valuable therapeutic strategy for HCC, potentially guiding future treatment approaches and improving patient outcomes.

## Linked entities

- **Genes:** PTEN (phosphatase and tensin homolog) [NCBI Gene 5728], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233], IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480], YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413]
- **Proteins:** PTEN (phosphatase and tensin homolog), MTOR (mechanistic target of rapamycin kinase), MET (MET proto-oncogene, receptor tyrosine kinase), IGF1R (insulin like growth factor 1 receptor), YAP1 (Yes1 associated transcriptional regulator)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480] {aka CD221, IGFIR, IGFR, JTK13}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, MIR122 (microRNA 122) [NCBI Gene 406906] {aka MIR122A, MIRN122, MIRN122A, hsa-mir-122, miRNA122, miRNA122A}, MIR375 (microRNA 375) [NCBI Gene 494324] {aka MIRN375, hsa-mir-375, miRNA375, mir-375}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}
- **Diseases:** tumour (MESH:D009369), HCC (MESH:D006528)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11975049/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11975049/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC11975049/full.md

---
Source: https://tomesphere.com/paper/PMC11975049